JP2014529398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014529398A5 JP2014529398A5 JP2014525119A JP2014525119A JP2014529398A5 JP 2014529398 A5 JP2014529398 A5 JP 2014529398A5 JP 2014525119 A JP2014525119 A JP 2014525119A JP 2014525119 A JP2014525119 A JP 2014525119A JP 2014529398 A5 JP2014529398 A5 JP 2014529398A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 23
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 23
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 8
- 229950004354 phosphorylcholine Drugs 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161521607P | 2011-08-09 | 2011-08-09 | |
| US61/521,607 | 2011-08-09 | ||
| PCT/US2012/049990 WO2013022968A1 (en) | 2011-08-09 | 2012-08-08 | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014529398A JP2014529398A (ja) | 2014-11-13 |
| JP2014529398A5 true JP2014529398A5 (enExample) | 2015-10-01 |
| JP6277126B2 JP6277126B2 (ja) | 2018-02-07 |
Family
ID=47668922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525119A Expired - Fee Related JP6277126B2 (ja) | 2011-08-09 | 2012-08-08 | ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9796786B2 (enExample) |
| EP (1) | EP2741770A4 (enExample) |
| JP (1) | JP6277126B2 (enExample) |
| CN (1) | CN103906532B (enExample) |
| AU (1) | AU2012294431B2 (enExample) |
| CA (1) | CA2843960C (enExample) |
| WO (1) | WO2013022968A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190988T1 (hr) | 2011-08-09 | 2019-09-20 | Athera Biotechnologies Ab | Nova protutijela protiv fosforilkolina |
| CN103906532B (zh) * | 2011-08-09 | 2018-01-26 | 阿瑟拉生物技术公司 | 结合磷酰胆碱（pc）和/或pc结合物的抗体 |
| US20150376268A1 (en) * | 2013-02-25 | 2015-12-31 | The Regents Of The University Of California | Antibodies to oxidized phospholipids |
| AR103442A1 (es) | 2015-01-16 | 2017-05-10 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
| MX2018009011A (es) | 2016-02-02 | 2018-11-19 | Hutchinson Fred Cancer Res | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. |
| KR20250173600A (ko) | 2023-03-17 | 2025-12-10 | 옥시토프 파마 비.브이. | 항-포스포콜린 항체 및 그 사용 방법 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402664A1 (fr) | 1977-09-07 | 1979-04-06 | Agronomique Inst Nat Rech | Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications |
| US5955584A (en) | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| DE3751182T2 (de) | 1986-08-06 | 1995-10-26 | Scripps Clinic Res | Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden. |
| JPH02188532A (ja) | 1989-01-17 | 1990-07-24 | Otsuka Pharmaceut Co Ltd | リポソームワクチン |
| AU5522390A (en) | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids |
| JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
| EP0562020A4 (en) | 1990-12-10 | 1993-11-18 | Alving, Carl L. | A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis |
| JPH07504817A (ja) | 1992-03-03 | 1995-06-01 | ザ ロックフェラー ユニヴァーシティ | Ｂ２９（Ｉｇ‐βまたはＩｇ−γ）を含むレセプタ複合体およびその利用 |
| WO1994014454A1 (en) | 1992-12-29 | 1994-07-07 | Entremed, Inc. | Vaccines against sterols |
| DE69411154T2 (de) | 1993-02-22 | 1998-10-22 | Alza Corp., Palo Alto, Calif. | Mittel zur oralen gabe von wirkstoffen |
| US5455032A (en) | 1993-07-29 | 1995-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Use of phosphocholine hapten conjugates in vaccines |
| AU1159497A (en) | 1996-11-08 | 1998-06-03 | Regents Of The University Of California, The | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6375925B1 (en) | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| US20040185039A1 (en) | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| DE69911417T2 (de) | 1998-07-03 | 2004-06-17 | Athera Biotechnologies Ab | Verfahren zur diagnose von gefässerkrankungen und früher atheriosklerose |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| DE60045869D1 (de) | 1999-10-26 | 2011-06-01 | Univ California | Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten |
| SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| AU2001259730A1 (en) | 2000-05-12 | 2001-11-26 | The Regents Of The University Of California | Standardized oxidized ldl assay |
| MXPA02012434A (es) * | 2000-06-16 | 2004-09-06 | Cambridge Antibody Tech | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US20070122419A1 (en) | 2003-04-11 | 2007-05-31 | The Regents Of The University Of California | Methods and compositions for treating atherosclerosis |
| WO2005100405A2 (en) | 2004-04-15 | 2005-10-27 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| ATE462802T1 (de) | 2004-09-08 | 2010-04-15 | Eisai R&D Man Co Ltd | Verfahren zur bildung eines signalsondenpolymers |
| NZ561218A (en) * | 2005-02-07 | 2011-04-29 | Univ California | Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells |
| EP1868651A4 (en) | 2005-04-12 | 2010-10-06 | Univ Duke | METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS |
| CA2631212A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| JP5122908B2 (ja) | 2007-10-17 | 2013-01-16 | 日泉化学株式会社 | 自動車の内装用部材の取り付け構造 |
| CN102124342A (zh) | 2008-07-07 | 2011-07-13 | 阿瑟拉生物技术公司 | 阿尔茨海默病新的治疗和诊断方法 |
| WO2010028306A2 (en) * | 2008-09-05 | 2010-03-11 | The Regents Of The University Of California Office Of The President | Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| HRP20190988T1 (hr) | 2011-08-09 | 2019-09-20 | Athera Biotechnologies Ab | Nova protutijela protiv fosforilkolina |
| CN103906532B (zh) * | 2011-08-09 | 2018-01-26 | 阿瑟拉生物技术公司 | 结合磷酰胆碱（pc）和/或pc结合物的抗体 |
-
2012
- 2012-08-08 CN CN201280048707.9A patent/CN103906532B/zh not_active Expired - Fee Related
- 2012-08-08 EP EP12821512.6A patent/EP2741770A4/en not_active Withdrawn
- 2012-08-08 WO PCT/US2012/049990 patent/WO2013022968A1/en not_active Ceased
- 2012-08-08 US US14/235,970 patent/US9796786B2/en not_active Expired - Fee Related
- 2012-08-08 AU AU2012294431A patent/AU2012294431B2/en not_active Ceased
- 2012-08-08 CA CA2843960A patent/CA2843960C/en not_active Expired - Fee Related
- 2012-08-08 JP JP2014525119A patent/JP6277126B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-28 US US15/719,508 patent/US20180086847A1/en not_active Abandoned
-
2021
- 2021-04-13 US US17/229,806 patent/US20210230310A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP6843090B2 (ja) | 血清アルブミンに結合するタンパク質 | |
| JP2014525233A5 (enExample) | ||
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| JP2014529398A5 (enExample) | ||
| JP2017508466A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2011526785A5 (enExample) | ||
| CN113307865B (zh) | 新型冠状病毒的全人源单域抗体及应用 | |
| JP2020023523A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2010502207A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2020529830A5 (enExample) | ||
| JP2015525211A5 (enExample) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2012518425A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2007097598A5 (enExample) | ||
| FI3527588T3 (fi) | Anti-FCRN-vasta-aineita | |
| JP2015143226A5 (enExample) |